Drug Trial Radar · NCT06903611
Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
475
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Nov 30, 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Cambium Bio LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for one year.
Conditions
- Dry Eye Disease
- Dry Eye
- Dry Eyes Chronic
- Dry Eye Syndromes
Interventions
CAM-101Drug
fibrinogen depleted human platelet lysate
Vehicle ControlOther
Plasmalyte-A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Corneal FluoresceinTime frame: 9 weeks
- Eye DiscomfortTime frame: 9 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.